AVR

Anteris Technologies Global Corp.

Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Inc. DE · CIK 0002011514
$9.34 -3.11% $909.2M
High Impact Filing (7/10)
Vol
Market Cap$909.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders6 funds
Inst. Value$5.8M
Inst. Activity2 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$35.4M
SEC Reports5
Exchange Nasdaq·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. DE·CIK 0002011514·Prev Close $9.64

Recent Activity

Jun 10, 2026 SEC
Director Susan Elizabeth Knight purchased $102K of AVR stock on the open market at $9.29/share, a conviction buy represe
INSIDER-BUY — Impact 4/10
Jun 8, 2026 other
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Jun 7, 2026 Insider
Moss Gregory S. sold 17,580 shares
Director @ $0.00 ($0.00)
Jun 7, 2026 Insider
Moss Gregory S. sold 17,580 shares
Director @ $0.00 ($0.00)
Jun 7, 2026 Insider
Roberts David B sold 17,580 shares
Director @ $0.00 ($0.00)
May 22, 2026 SEC
Anteris Technologies Global Corp. filed a 424B5 prospectus supplement for an at-the-market (ATM) offering of up to $250
424B5 — Impact 6/10
May 12, 2026 SEC
Anteris Technologies reported Q1 2026 EPS of -$0.74, a 174% miss vs consensus of -$0.27, with revenue of $1.1M in line.
PRESS-RELEASE — Impact 7/10
Inst.
BANK OF AMERICA CORP — DOUBLED
61,067 shares ($304.7K)

Price Targets

$15.33 +61.9% upside Strong Buy
Current $9.47 Low $15.00 Median $15.00 High $16.00 3 analysts
$15.00 $16.00

Analyst Ratings

Strong Buy88% buy · 8 analysts
1Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 15, 2026 Barclays MAINTAIN Overweight → Overweight
Mar 27, 2026 Cantor Fitzgerald REITERATE Overweight → Overweight
Mar 11, 2026 Wells Fargo INITIATE Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.22 ▼ -19.7% $-0.27 — $-0.16 62% YoY 4
Next Q $-0.25 ▼ -8.2% $-0.28 — $-0.21 59% YoY 4
Current FY $-1.08 ▼ -23.8% $-1.18 — $-0.95 58% YoY 3
Next FY $-0.98 ▼ -1.0% $-1.03 — $-0.92 9% YoY 3

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$4.2MADD
CHARLES SCHWAB INVESTMENT MANAGEMENT$503.5KADD
MORGAN STANLEY$401.1KADD
BANK OF AMERICA CORP$304.7KDOUBLED
FMR LLC$197.8KDOUBLED

Recent Insider Trades

DateInsiderTypeValue
Jun 7, 2026Moss GregoryM$0.00
Jun 7, 2026Moss GregoryM$0.00
Jun 7, 2026Roberts DavidM$0.00
Jun 7, 2026Roberts DavidM$0.00
Jun 5, 2026McDonnell MatthewM$0.00
6 institutional holders with $5.8M total value (1,160,483 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 2 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC841,339$4.2M72.5%ADD +85.1%
2CHARLES SCHWAB INVESTMENT MANAGEMENT INC100,911$503.5K8.7%ADD +87.3%
3MORGAN STANLEY80,378$401.1K6.9%ADD +49.7%
4BANK OF AMERICA CORP /DE/61,067$304.7K5.3%DOUBLED +474.4%
5FMR LLC39,631$197.8K3.4%DOUBLED +1984.5%
6WELLS FARGO & COMPANY/MN37,157$185.4K3.2%ADD +78.1%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BANK OF AMERICA CORP /DE/DOUBLED10,63161,067+474.4%$304.7K2025-Q4
WELLS FARGO & COMPANY/MNADD20,86637,157+78.1%$185.4K2025-Q4
VANGUARD GROUP INCADD402,849745,560+85.1%$3.4M2025-Q3
UBS Group AGTRIM301,158221,030-26.6%$994.6K2025-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD53,872100,911+87.3%$454.1K2025-Q3
WELLS FARGO & COMPANY/MNADD11,12220,866+87.6%$93.9K2025-Q3
BANK OF AMERICA CORP /DE/ADD7,83310,631+35.7%$47.8K2025-Q3
VANGUARD GROUP INCDOUBLED91,094402,849+342.2%$1.5M2025-Q2
UBS Group AGDOUBLED130,484301,158+130.8%$1.1M2025-Q2
MORGAN STANLEYADD47,70071,427+49.7%$270.7K2025-Q2
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD35,74853,872+50.7%$204.2K2025-Q2
FMR LLCDOUBLED1,59633,268+1984.5%$126.1K2025-Q2
WELLS FARGO & COMPANY/MNADD8,33111,122+33.5%$42.2K2025-Q2
UBS Group AGNEW130,484$475.0K2025-Q1
VANGUARD GROUP INCNEW91,094$331.6K2025-Q1
MORGAN STANLEYNEW47,700$173.6K2025-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW35,748$130.1K2025-Q1
WELLS FARGO & COMPANY/MNNEW8,331$30.3K2025-Q1
FMR LLCNEAR_EXIT584,2331,596-99.7%$5.8K2025-Q1
CITADEL ADVISORS LLCEXIT207,9200-100.0%$0.002025-Q1
CITADEL ADVISORS LLCNEW207,920$1.2M2024-Q4
5 unique insiders with 3 transactions. Net insider value: $35.4M ($35.4M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 7, 2026Moss Gregory S.DirectorM17,580$0.00$0.00
Jun 7, 2026Moss Gregory S.DirectorM17,580$0.00$0.00
Jun 7, 2026Roberts David BDirectorM17,580$0.00$0.00
Jun 7, 2026Roberts David BDirectorM17,580$0.00$0.00
Jun 5, 2026McDonnell MatthewChief Financial OfficerM2,001$0.00$0.00
Jun 5, 2026McDonnell MatthewChief Financial OfficerF39,595$9.83$389.2K
Jun 5, 2026McDonnell MatthewChief Financial OfficerM2,001$4.84$9.7K
Jun 2, 2026Knight Susan ElizabethDirectorBUY11,000$9.29$102.2K
Mar 4, 2026McDonnell MatthewChief Financial OfficerA78,740$0.00$0.00
Jan 22, 2026L1 Capital Pty Ltd10%+ OwnerBUY5,000,000$5.75$28.8M
Oct 28, 2025L1 Capital Pty Ltd10%+ OwnerBUY1,333,334$4.94$6.6M

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 1 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$15.33 mean target +61.9% upside Strong Buy (1.00)
$15.00 Low $16.00 High
MetricValue
Current Price$9.47
Target Low$15.00
Target Mean$15.33
Target Median$15.00
Target High$16.00
# Analysts3
RecommendationStrong Buy (1.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-0.22 $-0.27 $-0.16 61.8% -19.7% 1↑ 1↓ $0.0B 119.0% 4
Next Q
2026-09-30
$-0.25 $-0.28 $-0.21 59.0% -8.2% 1↑ 1↓ $0.0B 526.5% 4
Current FY
2026-12-31
$-1.08 $-1.18 $-0.95 57.6% -23.8% 1↑ 2↓ $0.0B 407.3% 3
Next FY
2027-12-31
$-0.98 $-1.03 $-0.92 9.3% -1.0% 2↑ 1↓ $0.0B 43.9% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.222
7d ago$-0.222
30d ago$-0.185-0.037
60d ago$-0.185-0.037
90d ago$-0.220-0.002
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 15, 2026 Barclays MAINTAIN Overweight Overweight
Mar 27, 2026 Cantor Fitzgerald REITERATE Overweight Overweight
Mar 11, 2026 Wells Fargo INITIATE Overweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20261610088%
May 1, 20261710089%
Apr 1, 20261710089%
Mar 1, 20261610088%
Feb 1, 20261610088%
Jan 1, 20261610088%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 8, 2026
other
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
May 26, 2026
short_volume
Short Volume: AVR — 55.8% short (0.3M / 0.6M)
Short: 343,181 | Exempt: 1,540 | TRF Vol: 614,954 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: AVR — 59.5% short (0.4M / 0.6M)
Short: 380,994 | Exempt: 0 | TRF Vol: 640,523 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: AVR — 60.7% short (0.3M / 0.5M)
Short: 332,621 | Exempt: 0 | TRF Vol: 547,582 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Appointment of Ms. Susan Knight and Mr. Stephen Denaro to the Board of Directors
May 12, 2026
earnings
Anteris Announces Results for the First Quarter of 2026
Anteris Announces Results for the First Quarter of 2026
May 11, 2026
earnings_calendar
AVR Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
other
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies Announces the First U.S. Patients Treated in the Global Pivotal PARADIGM Trial
Apr 28, 2026
other
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Technologies secures CMS reimbursement supporting U.S. site activation for the global pivotal PARADIGM Trial evaluating the DurAVR THV
Mar 23, 2026
short_interest
FTD: AVR — 180,523 shares ($1.0M) failed to deliver
Settlement: 20260323, Price: $5.60, FTD Value: $1,010,928.8, ANTERIS TECHNOLOGIES GLOBAL CO